ImageneBio, Inc.
IMAImageneBio, Inc. in brief
ImageneBio, Inc. is a listed company in the Biotechnology industry, based in Massachusetts, USA. It was founded in 2016. Its market value was $50 M on 27 October 2026, which makes it the 21,310th largest listed company in the world and the 3,855th largest in the USA on this site. In the year to December 2025 it had sales of $1 M and a net loss of $45 M. It employs about 67 people. Its shares trade under the symbol IMA (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About ImageneBio, Inc.
Biotechnology company with key focus on developing therapies for Cancer patients. Headquarters is in USA.
ImageneBio, Inc. timeline
- 2016
- 🏁· approximateFounded
- 2021
- 🔔· approximateInitial public offering on Nasdaq
- 💰Record revenue of $31 millionFY2021, the highest of the 6 years on record.
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 🔔Initial public offering as Ikena Oncology, Inc.Final prospectus filed with the SEC on 26 March 2021; shares registered for exchange trading on 23 March 2021.
- 2025
- ✎Renamed ImageneBio, Inc.Formerly Ikena Oncology, Inc..
Events of ImageneBio, Inc. from the company record, the company's financial years and SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #3,274 (Jan 2022) · #4,263 (Dec 2022) · #3,494 (Jul 2023) · #3,722 (Jan 2024) · #3,832 (Oct 2026) · #3,859 (Oct 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- 62.4×
- Price / book
- 0.4×
- Free cash flow yield
- -160.5%
- Net margin
- -5668.8%
- Operating margin
- -6056.3%
- Return on equity
- -34.1%
- Liabilities / assets
- 13.0%
- Revenue growth
- -77.1%
- R&D / revenue
- 3565.0%
- Revenue per employee
- $12 K
- Profit per employee
- $-677 K
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $1M | -77.1% | $-48M | $-45M | -5668.8% |
| Dec 2024 | $4M | -61.8% | $-37M | $-37M | -1044.9% |
| Dec 2023 | $9M | -41.4% | $-75M | $-68M | -744.2% |
| Dec 2022 | $16M | -49.6% | $-71M | $-69M | -440.2% |
| Dec 2021 | $31M | +237.1% | $-34M | $-34M | -110.1% |
| Dec 2020 | $9M | — | $-45M | $-44M | -481.6% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-48M | — | — | $-9.64 | — |
| Dec 2024 | $-21M | — | — | $-22.10 | — |
| Dec 2023 | $-80M | $0M | $-80M | $-1.63 | — |
| Dec 2022 | $-74M | $1M | $-76M | $-1.90 | — |
| Dec 2021 | $-60M | $2M | $-62M | $-1.22 | — |
| Dec 2020 | $-38M | $1M | $-39M | $-16.00 | — |
Quarterly results
Latest quarter to Sep 2026: revenue —, net income $-16M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 9, 202610-QQuarterly report · period to Sep 2026
- Nov 9, 20268-KCurrent reportResults of operations
- Aug 5, 202610-QQuarterly report · period to Jun 2026
- Aug 5, 20268-KCurrent reportResults of operations
- Jul 23, 20268-KCurrent reportDirectors or officers changed · Other events
- Jun 26, 20268-KCurrent reportDirectors or officers changed
- Jun 17, 20268-KCurrent reportDirectors or officers changed · Shareholder vote
- May 7, 20268-KCurrent reportResults of operations
- May 7, 202610-QQuarterly report · period to Mar 2026
- Apr 30, 2026DEF 14AProxy statement
- Apr 13, 20268-KCurrent reportMaterial agreement · Unregistered share sale
- Mar 17, 20268-KCurrent reportDirectors or officers changed
Official filings of ImageneBio, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $1 M
- Operating income
- $-48 M
- Net income
- $-45 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $153 M
- Total liabilities
- $20 M
- Total equity
- $133 M
As of December-2025
Top 37 institutional investors in ImageneBio, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Blue Owl Capital Holdings LP | 1,135,081 | +217,389 (+23.69%) | 9.11% | $5 M | Nov 13, 2026 |
| 2 | BVF Inc/il | 1,110,002 | 0 (0.00%) | 8.91% | $5 M | Nov 16, 2026 |
| 3 | Trails Edge Capital Partners, LP | 1,094,045 | +812,041 (+287.95%) | 8.78% | $5 M | Nov 16, 2026 |
| 4 | Orbimed Advisors LLC | 909,269 | 0 (0.00%) | 7.30% | $4 M | Nov 16, 2026 |
| 5 | Cable Car Capital, LP | 789,387 | +7,788 (+1.00%) | 6.34% | $4 M | Nov 16, 2026 |
| 6 | Omega Fund Management, LLC | 455,361 | 0 (0.00%) | 3.66% | $2 M | Nov 16, 2026 |
| 7 | Vanguard Capital Management LLC | 321,994 | +1,476 (+0.46%) | 2.58% | $1 M | Nov 13, 2026 |
| 8 | BML Capital Management, LLC | 200,730 | 0 (0.00%) | 1.61% | $1 M | Nov 6, 2026 |
| 9 | Monashee Investment Management LLC | 177,094 | -15,250 (-7.93%) | 1.42% | $1 M | Nov 6, 2026 |
| 10 | BlackRock, Inc. | 133,858 | -1,232 (-0.91%) | 1.07% | $1 M | Nov 13, 2026 |
| 11 | Renaissance Technologies LLC | 78,495 | -8,435 (-9.70%) | 0.63% | $0 M | Nov 12, 2026 |
| 12 | Geode Capital Management, LLC | 67,537 | +14,025 (+26.21%) | 0.54% | $0 M | Nov 6, 2026 |
| 13 | Adage Capital Partners GP, L.L.C. | 66,666 | 0 (0.00%) | 0.54% | $0 M | Nov 16, 2026 |
| 14 | Stonepine Capital Management, LLC | 57,663 | New | 0.46% | $0 M | Nov 13, 2026 |
| 15 | NEA Management Company, LLC | 50,005 | 0 (0.00%) | 0.40% | $0 M | Nov 16, 2026 |
| 16 | Nano Cap New Millennium Growth Fund L P | 50,000 | 0 (0.00%) | 0.40% | $0 M | Nov 13, 2026 |
| 17 | Vanguard Fiduciary Trust Co | 49,261 | +21,786 (+79.29%) | 0.40% | $0 M | Nov 13, 2026 |
| 18 | Millennium Management LLC | 40,386 | New | 0.32% | $0 M | Nov 16, 2026 |
| 19 | HSBC Holdings PLC | 34,228 | 0 (0.00%) | 0.27% | $0 M | Nov 16, 2026 |
| 20 | Sofinnova Investments, Inc. | 31,884 | 0 (0.00%) | 0.26% | $0 M | Nov 16, 2026 |
| 21 | Two Sigma Investments, LP | 20,900 | +1,000 (+5.03%) | 0.17% | $0 M | Nov 16, 2026 |
| 22 | Rangeley Capital, LLC | 20,090 | 0 (0.00%) | 0.16% | $0 M | Nov 16, 2026 |
| 23 | Shay Capital LLC | 18,205 | +125 (+0.69%) | 0.15% | $0 M | Nov 16, 2026 |
| 24 | Aldebaran Capital, LLC | 17,747 | -377 (-2.08%) | 0.14% | $0 M | Nov 13, 2026 |
| 25 | Northern Trust Corp | 11,271 | 0 (0.00%) | 0.09% | $0 M | Nov 16, 2026 |
Show all 37: investors 26 to 37
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Goldman Sachs Group Inc | 10,926 | -4,559 (-29.44%) | 0.09% | $0 M | Nov 16, 2026 |
| 27 | Barclays PLC | 10,797 | 0 (0.00%) | 0.09% | $0 M | Nov 6, 2026 |
| 28 | Morgan Stanley | 9,166 | -7,512 (-45.04%) | 0.07% | $0 M | Nov 13, 2026 |
| 29 | UBS Group AG | 7,163 | +284 (+4.13%) | 0.06% | $0 M | Nov 10, 2026 |
| 30 | Tower Research Capital LLC (TRC) | 1,046 | +371 (+54.96%) | 0.01% | $0 M | Nov 16, 2026 |
| 31 | Vanguard Global Advisers, LLC | 602 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 32 | Caitong International Asset Management Co., Ltd | 464 | 0 (0.00%) | 0.00% | $0 M | Oct 29, 2026 |
| 33 | Elequin Capital, LP | 385 | New | 0.00% | $0 M | Nov 13, 2026 |
| 34 | FMR LLC | 360 | New | 0.00% | $0 M | Nov 10, 2026 |
| 35 | NewEdge Advisors, LLC | 160 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 36 | Jpmorgan Chase & Co | 70 | 0 (0.00%) | 0.00% | $0 M | Nov 12, 2026 |
| 37 | BNP Paribas Financial Markets | 24 | 0 (0.00%) | 0.00% | $0 M | Nov 12, 2026 |
Mutual funds holding ImageneBio, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 264,771 | $2 M | 2.1% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 52,467 | $0 M | 0.42% | <0.01% | −0.4% | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 31,679 | $0 M | 0.25% | <0.01% | +16% | May 31, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 26,707 | $0 M | 0.21% | 0.01% | +29% | Jun 30, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 7,299 | $0 M | 0.06% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 5,821 | $0 M | 0.05% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 4,219 | $0 M | 0.03% | <0.01% | +122% | May 31, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 3,280 | $0 M | 0.03% | <0.01% | −58% | Jun 30, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 1,787 | $0 M | 0.01% | <0.01% | +9.7% | Jun 30, 2026 |
| 🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC | 434 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 10 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at ImageneBio, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Yanina Grant-HuertaChief Financial Officer | Grant or award | +65,000 | — | — | 65,000 | Form 4 |
| filed | Kristin YaremaChief Executive Officer, Director | Grant or award | +254,800 | — | — | 493,705 | Form 4 |
| filed | Yanina Grant-HuertaChief Financial Officer | Grant or award | +39,000 | — | — | 104,000 | Form 4 |
| filed | Kristin YaremaChief Executive Officer, Director | Option exercise | +38,376 | — | — | 123,776 | Form 4 |
| filed | Kristin YaremaChief Executive Officer, Director | Other | +115,129 | — | — | 238,905 | Form 4 |
| filed | Robert B. LallyPrincipal Accounting Officer | Sell | -1,525 | $5.340 | $8 K | 55,582 | Form 4 |
| filed | Robert B. LallyPrincipal Accounting Officer | Sell | -1,671 | $5.500 | $9 K | 57,107 | Form 4 |
| filed | Kristin YaremaChief Executive Officer, Director | Grant or award | +85,400 | — | — | 85,400 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: ImageneBio, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-7.16 reverse split
| Buybacks, quarter | Fiscal | Spent |
|---|---|---|
| Q4 2023 | Q4 2023 | $0M |
| Q3 2023 | Q3 2023 | $0M |
Trading halts
- 2025-09-04 13:58 UTC, code LUDP, resumed 14:03 UTC
- 2025-07-25 23:50 UTC, code D, resumed 04:00 UTC
- 2025-07-25 23:50 UTC, code T3, resumed 13:00 UTC
- 2024-12-23 13:25 UTC, code T3, resumed 14:00 UTC
Fails to deliver
- : 2,000 shares at $4.01
- : 4,446 shares at $4.13
- : 2,046 shares at $4.09
- : 300 shares at $4.59
- : 152 shares at $4.64
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
ImageneBio, Inc. scorecard#
Passes 2 of the 13 checks that could be worked out: strongest in financial health (1 of 3), weakest in growth (0 of 3). Fiscal year 2025; market cap of Oct 27, 2026.
Valuation1 of 5
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✓Price to book below its peers' median0.4×Price to book 0.4× against Biotechnology's median of 2.9×.
- ✗Price to sales below its peers' median62.4×Price to sales 62.4× against Biotechnology's median of 8.7×.
- ✗Free cash flow yield above 5%-160.5%Free cash flow is -160.5% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth0 of 3
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-9.64 vs -22.10Diluted EPS -9.64 in fiscal 2025 against -22.10 the year before (report's currency).
- ✗Net income higher than five years earlier-$45 M-$45 M in fiscal 2025 against -$44 M in 2020.
- ✗Revenue rose in at least four of the last five years1 of 5Revenue rose in 1 of the five years to fiscal 2025.
Profitability0 of 2
- ✗Profitable in the newest year-$45 MNet income -$45 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- –Return on equity above 15%No return on equity (equity missing or negative).
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 3
- ✓Short-term assets cover short-term liabilities12.5×Current ratio 12.49 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- ✗Altman Z-score outside the distress zone-0.62Z-score -0.62 (distress zone) for fiscal 2025.
Shareholder returnsnot known
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- –Share count up no more than 2% in a yearShare counts of two years are not on file.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
ImageneBio, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 0.8−77.1%100% | 3.5−61.8%100% | 9.2−41.3%100% | 16−49.6%100% | 31+237%100% | 9.2—100% | |
| Research and development | 29−11.2%3566% | 32r31−46.2%917% | 60−7.3%651% | 64+36.5%412% | 47+5.0%152% | 45—488% | |
| General and administrative | 21+147%2591% | 8.4r24−66.3%240% | 25+12.3%272% | 22+23.2%142% | 18+103%58.1% | 8.9—96.4% | |
| Operating expenses | 49+21.6%6156% | 41r59−52.1%1157% | 85−2.2%923% | 87+32.9%554% | 65+21.2%210% | 54—584% | |
| Operating income | −48—−6056% | −37r−59—−1057% | −75—−823% | −71—−454% | −34—−110% | −45—−484% | |
| Interest and finance income | — | — | 7.1+231%77.6% | 2.1+9243%13.8% | 0.0—0.1% | — | |
| Other non-operating income (expense) | 2.8+518%344% | 0.4r9.9−93.7%12.7% | 7.1+231%77.4% | 2.1+9200%13.7% | 0.0−91.3%0.1% | 0.3—2.9% | |
| Income before tax | −46—−5712% | −37r−49—−1044% | −68—−746% | −69—−440% | — | — | |
| Income tax | −0.4−2792%−43.8% | 0.0r0.2—0.4% | −0.2—−1.8% | 0—0.0% | 0—0.0% | — | |
| Net income including minority interests | −45—−5669% | −37r−49—−1045% | −68—−744% | −69—−440% | −34—−110% | −44—−481% | |
| Net income attributable to shareholders | −45—−5669% | −37r−49—−1045% | −68—−744% | −69—−440% | −34—−110% | −44—−481% | |
| Earnings per share, basic | -9.64—— | -22.10r-1.02—— | -1.63—— | -1.90—— | -1.22—— | -16.00—— | |
| Earnings per share, diluted | -9.64—— | -22.10r-1.02—— | -1.63—— | -1.90—— | -1.22—— | -16.00—— | |
| Shares, weighted average (basic) | 4.9+308%— | 1.2r48−97.1%— | 42+15.3%— | 36+29.3%— | 28—— | — | |
| Shares, weighted average (diluted) | — | 48+15.6%— | 42+15.3%— | 36+29.3%— | 28+912%— | 2.8—— | |
| Balance sheet | |||||||
| Cash and cash equivalents | 95+680%61.8% | 12r39−89.9%76.1% | 120+100%62.4% | 60−74.2%34.8% | 232+42.9%93.7% | 162—96.5% | |
| Short-term investments | 41—26.7% | 0r85−100%0.0% | 56−42.7%28.9% | 97—56.3% | — | — | |
| Other current assets | 4.9+1311%3.2% | 0.4r2.8−69.6%2.2% | 1.2+19.3%0.6% | 1.0+53.3%0.6% | 0.6−59.1%0.3% | 1.5r1.6—0.9% | |
| Current assets | 140+1025%91.7% | 12r127−93.0%78.3% | 179+11.7%93.0% | 160−32.3%92.9% | 237+42.5%95.4% | 166—98.6% | |
| Property, plant and equipment | 0−100%0.0% | 0.0r0.6−99.7%0.1% | 2.3−27.1%1.2% | 3.2+31.4%1.9% | 2.4+75.1%1.0% | 1.4—0.8% | |
| Right-of-use (leased) assets | 0.8+44.4%0.5% | 0.5r3.6−90.4%3.4% | 5.7+8.2%3.0% | 5.3−19.6%3.1% | 6.5+3746%2.6% | 0.2—0.1% | |
| Total assets | 153+861%100% | 16r142−91.7%100% | 192+11.5%100% | 172−30.5%100% | 248+47.2%100% | 168—100% | |
| Accounts payable | 1.4−72.8%0.9% | 5.3r0.9+156%33.2% | 2.1−1.3%1.1% | 2.1−12.2%1.2% | 2.4+12.3%1.0% | 2.1—1.3% | |
| Debt due within a year | 0−100%0.0% | 7.5—47.1% | — | — | — | — | |
| Current liabilities | 11−34.7%7.3% | 17r11+21.1%108% | 14−33.9%7.4% | 22−20.9%12.5% | 27−4.0%11.0% | 28—16.8% | |
| Lease liabilities (non-current) | 0.7+198%0.5% | 0.2r3.7−96.7%1.5% | 7.2+89.6%3.7% | 3.8−26.3%2.2% | 5.1—2.1% | 0—0.0% | |
| Total liabilities | 20+13.7%13.0% | 17r16−21.9%110% | 22−11.7%11.6% | 25−36.8%14.7% | 40−37.0%16.1% | 63—37.7% | |
| Retained earnings | −230—−150% | −180r−332—−1130% | −282—−147% | −214—−124% | −145—−58.7% | −111—−66.1% | |
| Shareholders' equity | 133—87.0% | −161r126—−1008% | −126r170−186%−65.6% | 147−29.3%85.3% | 208—83.9% | −101—−60.0% | |
| Total liabilities and equity | 153+861%100% | 16r142−91.7%100% | 192+11.5%100% | 172−30.5%100% | 248+47.2%100% | 168—100% | |
| Shares outstanding | — | 480.0%— | 48+33.1%— | 36+0.8%— | 36+1062%— | 3.1—— | |
| Cash-flow statement | |||||||
| Depreciation and amortization | 0.4−63.6%50.0% | 1.1—31.4% | — | — | — | — | |
| Share-based compensation | 15—1924% | 0r5.3−100%0.0% | 7.6+1.4%83.3% | 7.5+45.4%48.2% | 5.2+188%16.7% | 1.8—19.5% | |
| Cash from operating activities | −48—−5981% | −21r−46—−609% | −80—−871% | −74—−475% | −60—−194% | −38—−411% | |
| Capital expenditure | — | — | −0.4—−4.5% | −1.4—−9.2% | −1.8—−5.7% | −0.8—−8.3% | |
| Cash from investing activities | −5.8−152%−727% | 11r−35−82.7%318% | 64—700% | −99—−636% | −1.8−160%−5.7% | 2.9—31.8% | |
| Debt issued | 15+100%1875% | 7.5—214% | — | — | — | — | |
| Shares issued | — | — | 37—409% | — | — | — | |
| Shares bought back | — | — | −0.7—−7.2% | — | — | — | |
| Cash from financing activities | 135+1862%16934% | 6.9−90.9%197% | 76+6839%829% | 1.1−99.2%7.0% | 132+13.4%425% | 116—1264% | |
| Exchange-rate effect on cash | 0.6+594%75.5% | 0.1—2.5% | — | — | — | — | |
| Change in cash | 82—10302% | −3.2—−91.5% | — | — | — | — | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | — | — | — | — | 0*—— | 0−100%— | 0*—— | 0.8—100% | 0*−100%— | 3.5—100% | — | — | 0.7*—100% | |
| Research and development | 28−3.6%— | 11−25.6%— | 6.7+18.0%— | 6.0+47.5%— | 3.7r3.3*−2.2%— | 15r16+290%— | 5.7r4.0−42.5%— | 4.0r3.7−58.1%505% | 3.8r4.6*−73.7%— | 3.9r6.8—111% | 9.8—— | 9.6—— | 14*—2166% | |
| General and administrative | 23+25.9%— | 6.0−45.3%— | 5.1+200%— | 6.1+122%— | 5.2*+119%— | 11+568%— | 1.7r4.4−67.9%— | 2.8r5.6−54.1%344% | 2.4r7.6*−71.3%— | 1.7r4.8—47.2% | 5.3—— | 6.0—— | 8.3*—1258% | |
| Operating expenses | 50+7.7%— | 17−33.9%— | 12+60.2%— | 12+77.8%— | 8.9r8.5*+45.0%— | 26r27+373%— | 7.4r8.8−53.5%— | 6.8r11−62.7%849% | 6.1r13*−72.8%— | 5.5r12—158% | 16—— | 18—— | 23*—3424% | |
| Operating income | −50—— | −17—— | −12—— | −12—— | −8.9r−8.5*—— | −26r−27—— | −7.4r−8.8—— | −6.0r−11—−749% | −6.1r−13*—— | −2.0r−12—−58.2% | −16—— | −18—— | −22*—−3324% | |
| Interest and finance income | — | — | — | — | — | — | — | — | — | — | — | — | 2.3*—345% | |
| Other non-operating income (expense) | 6.5+175%— | 1.7+27.6%— | 1.6—— | 1.5—— | 1.7r1.3*+28.2%— | 1.3r1.7—— | −0.2r6.0−111%— | −0.1r2.2−104%−10.3% | 1.3r3.4*−40.5%— | −1.1r2.2—−32.8% | 2.2—— | 2.1—— | 2.3*—342% | |
| Income before tax | −44—— | −16—— | −10—— | −11—— | −7.2*—— | −25—— | −7.6r−2.8—— | −6.1r−8.6—−760% | −4.8r−9.1*—— | −3.2r−10—−90.9% | −14—— | −16—— | −20*—−2982% | |
| Income tax | −0.2—— | 0.0—— | 0.0+6.7%— | 0.0−64.3%— | −0.3*−2223%— | −0.1—— | 0.0−75.8%— | 0.0+3.7%3.5% | 0.0r0.1*—— | 0r0.0—0.0% | 0.1—— | 0.0—— | — | |
| Net income including minority interests | −43—— | −16*—— | −10*—— | −11—— | −6.9*—— | −25r−27*—— | −7.6r−2.8*—— | −6.1r−8.6—−760% | −4.8r−9.1*—— | −1.9r−10*—−53.7% | −14*—— | −16—— | −19*—−2957% | |
| Net income attributable to shareholders | −43—— | −16—— | −10—— | −11—— | −6.9*—— | −25—— | −7.6r−2.8—— | −6.1r−8.6—−760% | −4.8r−9.1*—— | −3.2r−10—−90.9% | −6.3r−14—— | −22r−16—— | −19*—−2957% | |
| Earnings per share, basic | — | -0.91—— | -0.63—— | -0.95—— | — | -2.91—— | -4.46r-0.06—— | -3.80r-0.18—— | — | -2.58r-0.21—— | -0.28—— | -0.33—— | — | |
| Earnings per share, diluted | — | -0.91—— | -0.63—— | -0.95—— | — | -2.91—— | -4.46r-0.06—— | -3.80r-0.18—— | — | -2.58r-0.21—— | -0.28—— | -0.33—— | — | |
| Shares, weighted average (basic) | 17+94.6%— | 17+94.6%— | — | 11+695%— | — | 8.8r8.5+528%— | 480.0%— | 1.4r48−97.1%— | — | 1.4r48—— | 48—— | 48—— | — | |
| Shares, weighted average (diluted) | 17+94.6%— | 17+94.6%— | 16+572%— | 11+366%— | — | 8.8−81.8%— | 2.4r48−95.0%— | 2.4r48−95.0%— | — | 48—— | 48—— | 48—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 85—59.5% | 85−17.7%59.5% | 95+62.4%62.3% | 76+107%55.6% | 95+680%61.8% | 103+128%64.1% | 58+31.7%46.2% | 37−30.4%28.1% | 12r39−89.9%76.1% | 45—30.3% | 44—28.1% | 53—30.6% | 120—62.4% | |
| Short-term investments | 42—29.3% | 42+5.9%29.3% | 41+11.0%27.3% | 41−46.7%30.1% | 41—26.7% | 39−57.5%24.5% | 37−63.1%29.6% | 77−26.0%59.1% | 0r85−100%0.0% | 93—62.3% | 101—64.2% | 104—60.5% | 56—28.9% | |
| Other current assets | 4.0—2.8% | 4.0−19.2%2.8% | 5.0+47.1%3.3% | 4.8+62.8%3.5% | 4.9+1311%3.2% | 4.9+41.4%3.1% | 3.4−13.6%2.7% | 2.9−22.8%2.3% | 0.4r2.8−69.6%2.2% | 3.5—2.3% | 3.9—2.5% | 3.8—2.2% | 1.2—0.6% | |
| Current assets | 131—91.6% | 131−11.5%91.6% | 141+42.5%92.8% | 122+4.3%89.3% | 140+1025%91.7% | 148+4.2%91.7% | 99−33.7%78.5% | 117−27.4%89.4% | 12r127−93.0%78.3% | 142—95.0% | 149—94.8% | 161—93.3% | 179—93.0% | |
| Property, plant and equipment | — | — | — | — | 0−100%0.0% | 0.0−99.9%0.0% | 0.4−45.7%0.3% | 0.5−41.4%0.4% | 0.0r0.6−99.7%0.1% | 0.7—0.5% | 0.8—0.5% | 0.9—0.5% | 2.3—1.2% | |
| Right-of-use (leased) assets | 0.3—0.2% | 0.3−61.0%0.2% | 0.5−79.7%0.3% | 0.6−80.1%0.5% | 0.8+44.4%0.5% | 0.9−78.8%0.5% | 2.6−46.4%2.0% | 3.1−40.8%2.4% | 0.5r3.6−90.4%3.4% | 4.2—2.8% | 4.8—3.0% | 5.2—3.0% | 5.7—3.0% | |
| Total assets | 143—100% | 143−11.4%100% | 152+20.5%100% | 137+4.5%100% | 153+861%100% | 161+8.0%100% | 126−19.9%100% | 131−24.3%100% | 16r142−91.7%100% | 149—100% | 157—100% | 173—100% | 192—100% | |
| Accounts payable | 0.9—0.7% | 0.9−55.3%0.7% | 1.0+90.8%0.6% | 0.6−29.4%0.4% | 1.4−72.8%0.9% | 2.1+35.1%1.3% | 0.5−63.6%0.4% | 0.8−57.8%0.6% | 5.3r0.9+156%33.2% | 1.5—1.0% | 1.4—0.9% | 1.9—1.1% | 2.1—1.1% | |
| Debt due within a year | — | — | — | — | 0−100%0.0% | 0—0.0% | — | — | 7.5—47.1% | — | — | — | — | |
| Current liabilities | 8.1—5.7% | 8.1−27.5%5.7% | 6.6−10.3%4.3% | 6.6−24.6%4.9% | 11−34.7%7.3% | 11+20.6%6.9% | 7.3−10.6%5.8% | 8.8−13.5%6.7% | 17r11+21.1%108% | 9.2—6.2% | 8.2—5.2% | 10—5.9% | 14—7.4% | |
| Lease liabilities (non-current) | 0—0.0% | 0−100%0.0% | 0−100%0.0% | 0.1−96.0%0.1% | 0.7+198%0.5% | 1.3−71.3%0.8% | 1.8−65.9%1.5% | 2.7−56.9%2.1% | 0.2r3.7−96.7%1.5% | 4.5—3.0% | 5.4—3.4% | 6.3—3.6% | 7.2—3.7% | |
| Total liabilities | 14—10.1% | 14−31.6%10.1% | 10.0−2.8%6.6% | 13+6.1%9.8% | 20+13.7%13.0% | 21+42.6%13.1% | 10−29.9%8.1% | 13−27.8%9.6% | 17r16−21.9%110% | 15—9.9% | 15—9.3% | 17—10.1% | 22—11.6% | |
| Retained earnings | −266—−187% | −266—−187% | −251—−165% | −241—−176% | −230—−150% | −223—−139% | −343—−272% | −340—−260% | −180r−332—−1130% | −322—−216% | −312—−198% | −299—−173% | −282—−147% | |
| Shareholders' equity | 128—89.9% | 128−8.4%89.9% | 142—93.4% | 123—90.2% | 133—87.0% | 140—86.9% | −180r116—−143% | −170r118—−130% | −161r126—−1008% | −153r134—−103% | −147r143—−93.1% | −137r155—−79.5% | −126r170—−65.6% | |
| Total liabilities and equity | 143—100% | 143−11.4%100% | 152+20.5%100% | 137+4.5%100% | 153+861%100% | 161+8.0%100% | 126−19.9%100% | 131−24.3%100% | 16r142−91.7%100% | 149—100% | 157—100% | 173—100% | 192—100% | |
| Shares outstanding | — | — | — | — | — | — | 480.0%— | 480.0%— | 480.0%— | 48—— | 48—— | 48—— | 48—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 0.4+1538%— | 0*−100%— | 0*−100%— | 0−100%— | 0.4*+2083%— | 0.0*—— | 0.0*—— | 0.0—0.3% | 0.0*—— | — | — | — | — | |
| Share-based compensation | 3.5−77.2%— | 1.7−89.1%— | 0.9—— | 0.9+1437%— | 0.1*—— | 15+1403%— | 0r0.5−100%— | 0.1r0.9−97.2%7.1% | 0r1.0*−100%— | 1.0—29.1% | 1.3—— | 2.0—— | 1.8*—266% | |
| Cash from operating activities | −41—— | −9.5*—— | −9.1*—— | −15—— | −7.2*—— | −21r−27*−266%— | −12r−3.4*—— | −7.2r−11—−904% | −3.5r−6.3*—— | 13r−8.9*—370% | −13*—— | −18—— | −22*—−3311% | |
| Capital expenditure | — | — | — | — | — | — | — | — | — | — | — | — | −0.3*—−39.8% | |
| Cash from investing activities | −2.5—— | −0.4*—— | −0.3*—— | −0.4—— | −1.4*−1424%— | −4.5r−37*−108%— | 0r25*−100%— | 0r7.9—0.0% | 0.1r0.5*−99.5%— | 56r9.5*—1595% | 3.9*—— | −49—— | 20*—3092% | |
| Debt issued | — | 0*—— | — | — | 0*−100%— | 0*—— | — | — | 7.5*—— | — | — | — | — | |
| Shares issued | — | — | — | — | — | — | — | — | — | — | — | — | 0*—0.0% | |
| Shares bought back | — | — | — | — | — | — | — | — | — | — | — | — | 0*—0.0% | |
| Cash from financing activities | 25−82.5%— | 0.1*−99.9%— | 28*+115%— | −3.2−12115%— | 0*−100%— | 122*—— | 13*—— | 0.0—3.4% | 6.9*+11410%— | — | — | — | 0.1*—9.1% | |
| Exchange-rate effect on cash | −0.0−108%— | 0*−100%— | 0*—— | 0−100%— | −0.0*—— | 0.7*—— | −0.0*—— | 0.0—0.4% | −0.0*—— | — | — | — | — | |
| Change in cash | −18−119%— | −9.8*−110%— | 19*+1589%— | −18—— | −8.6*−346%— | 97*—— | 1.1*—— | −7.2—−900% | 3.5*—— | — | — | — | — | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Where ImageneBio, Inc. operates: 3 countries#
Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 7 subsidiaries on file.
| Country | Presence | Revenue there |
|---|---|---|
| 🇺🇸 USA | Headquarters1 office5 subsidiaries | — |
| 🇻🇬 British Virgin Islands | 1 subsidiary | — |
| 🇰🇾 Cayman Islands | 1 subsidiary | — |
Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided
Events at ImageneBio, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
- Auditor changedFiling
Auditor changed 1 · Change in control 2 · Acquisition or sale completed 2 · Directors and officers 14 · Material agreement 4 · Agreement ended 1 · Unregistered share sale 3 · Shareholder rights changed 1 · Bylaws or fiscal year changed 1 · Shareholder vote 2 · Results announced 5
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Results announced | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Material agreementAgreement ended | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Acquisition or sale completed | 8-K/A | |
| Auditor changed | 8-K | |
| Directors and officers | 8-K | |
| Change in controlAcquisition or sale completedDirectors and officersMaterial agreementUnregistered share saleShareholder rights changedBylaws or fiscal year changed | 8-K | |
| Directors and officers | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Change in controlDirectors and officersMaterial agreementUnregistered share sale | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 9, 2026
Acquisitions and funding#
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Aug 2023 | $43 M | Private placement after listing | $10 to $50 million | 48 | equity | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
From US state WARN notices and SEC 8-K restructuring filings, newest first.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | · | · | · | · | · | · | · | · | · | · | · | · | — |
| Announced | People | Kind | Where | Source |
|---|---|---|---|---|
| 53% of workforce | Restructuring planSEC 8-K | “(the “Company”) approved a plan to discontinue the clinical development of IK-930, continue clinical development of IK-595 and reduce its current workforce by approximately 53% (th…” | Filing | |
| 35% of workforce | Restructuring planSEC 8-K | “On January 17, 2024, the Board of Directors of the Company approved a plan to reduce the Company’s workforce by approximately 35% (the “Workforce Reduction”).” | Filing |
Source: State WARN notices and SEC 8-K item 2.05
How ImageneBio, Inc. compares in Biotechnology
- Market cap$50 M · higher than 26% of 726
- Revenue$1 M · higher than 23% of 647
- Revenue growth-77.1% · higher than 8% of 438
- Price / sales62.4× · lower than 15% of 339
- Price / book0.4× · lower than 96% of 534
- FCF yield-160.5% · higher than 4% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| ImageneBio, Inc.🇺🇸 | $50 M | — | — | -77.1% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 27, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As on 2021
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at ImageneBio, Inc.? Verify and update this profile — free
Show ImageneBio, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.